Roman Butler Fullerton & Co. acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 31,505 shares of the biotechnology company’s stock, valued at approximately $378,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of ADMA Biologics in the first quarter valued at approximately $17,221,000. Rice Hall James & Associates LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter worth $7,963,000. Castleark Management LLC bought a new position in shares of ADMA Biologics during the 1st quarter worth $5,400,000. Hillsdale Investment Management Inc. grew its position in shares of ADMA Biologics by 41,893.3% during the 1st quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock worth $4,157,000 after buying an additional 628,400 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after buying an additional 556,175 shares during the period. 75.68% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, CEO Adam S. Grossman sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at approximately $22,313,412. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.70% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on ADMA
ADMA Biologics Stock Performance
ADMA stock traded up $0.82 during midday trading on Tuesday, reaching $17.27. The stock had a trading volume of 4,942,288 shares, compared to its average volume of 3,042,754. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21. The firm has a fifty day simple moving average of $11.90 and a two-hundred day simple moving average of $8.47. The stock has a market cap of $4.00 billion, a PE ratio of -848.00 and a beta of 0.55. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $17.30.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same period last year, the company earned ($0.02) earnings per share. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current year.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
- Five stocks we like better than ADMA Biologics
- Which Wall Street Analysts are the Most Accurate?
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Financial Services Stocks Investing
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.